What if meaningful progress in neurological care comes not from entirely new inventions, but from refining how we support the brain’s existing systems? Across Parkinson’s disease, stroke, and age-related decline, researchers are uncovering a shared theme: better control of inflammation, smarter use of drug combinations, and improved cellular “cleanup” may play a central role in preserving function. Clinical observations suggest that amantadine-based combinations could help stabilize movement in Parkinson’s while reducing reliance on higher medication doses, while experimental work in stroke points to compounds like atractylodin that may protect the brain by calming damaging inflammatory responses.
At a deeper level, emerging research is also revealing biological pathways that keep the brain’s immune cells functioning in a more youthful, repair-supportive state, helping clear debris and promote myelin repair. Taken together, these findings highlight a shift in focus: not just treating disease symptoms, but enhancing the brain’s ability to protect and restore itself. That shift could reshape how we approach recovery across a wide range of neurological conditions.
1. Amantadine-based combination therapy of Parkinson’s disease to prevent fluctuation and dyskinesia – experiences from a Parkinson outpatient clinic
A long-term outpatient clinic study suggests that an amantadine-based drug combination may help people with Parkinson’s delay fluctuations and dyskinesia while reducing reliance on higher-dose levodopa. The results are encouraging, though stronger prospective studies are still needed.
2. Atractylodin alleviates neuroinflammation and protects neurological function after ischemic stroke in association with reduced NLRP3 inflammasome activation
Atractylodin helped reduce post-stroke brain inflammation and protected neurological function in experimental models, partly by calming NLRP3-driven inflammatory damage. The findings suggest it may be a promising therapeutic candidate for ischemic stroke.
3. Aurka-Bhlhe41 axis prevents premature aging-like microglial dysfunction and promotes remyelination
This study identifies an Aurka-Bhlhe41 pathway that helps keep microglia functioning in a more youthful, repair-supportive state, allowing better cleanup of myelin debris and improved remyelination. It also points to CD22 as a promising target for slowing age-related decline in myelin repair.
If you’d like to stay informed of the latest publications and breakthroughs in neuron regeneration, join our email newsletter to the right (or below on mobile). We send out weekly updates with the latest papers and studies, as well as podcast episodes with the people driving Neuroregenerative breakthroughs.
